A Randomized, Double-blind, Single-dose, Parallel-group Design, 2 Arm Study Comparing the Pharmacokinetic, Pharmacodynamic, Safety, Tolerability, and Immunogenicity Profiles of AVT03 and Prolia® in Healthy Male Subjects
Latest Information Update: 31 May 2024
At a glance
- Drugs Denosumab (Primary)
- Indications Osteoporosis
- Focus Pharmacokinetics
- Sponsors Alvotech
- 05 Apr 2024 Status changed from active, no longer recruiting to completed.
- 29 Jan 2024 Results presented in an Alvotech Media Release.
- 18 Oct 2023 Planned End Date changed from 17 Oct 2023 to 20 Dec 2023.